{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.70","upperLimit":"74.48","value":"48.3"},{"groupId":"OG001","lowerLimit":"26.05","upperLimit":"47.44","value":"37.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"description":"High-risk population included but not be limited to participants carrying cytogenetic deletion (del)17, translocation \\[t\\](4;14), t(14;16). OS was measured as the time from the date of randomization to the date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib placebo-matching capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.","id":"OG000","title":"Placebo"},{"description":"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.","id":"OG001","title":"Ixazomib"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants who were randomized and had post-randomization data. Overall number of participants analyzed is the number of participants present in the high-risk group.","reportingStatus":"POSTED","timeFrame":"From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months)","title":"OS in a High-risk Population","type":"SECONDARY","unitOfMeasure":"months"}